Kymera Therapeutics, Inc. Common Stock (KYMR) Financial Statements
Historical financial data — 21 statements covering FY2020–FY2025
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health...
Kymera Therapeutics, Inc. Common Stock's revenue decreased 16.7% year over year, from $47.1M to $39.2M.
Net income decreased 39.1% over the same period, from $-223.9M to $-311.4M.
Over the 5-year period from FY2020 to FY2025, revenue grew by 15% in total.
Operating cash flow declined 19.7% to $-232.9M.
Kymera Therapeutics, Inc. Common Stock maintains a negative net profit margin of -794.0%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $35.9M+660.1% | $-90.6M | N/A | $-108.8M | $-82.5M | $826.0M | N/A | $684.9M |
| Q3 FY2024 | $3.7M-89.6% | $-62.5M | N/A | $-72.1M | $-50.2M | $1.03B | N/A | $892.9M |
| Q4 FY2024 | $7.4M+97.6% | $-70.8M | N/A | $-80.8M | $-61.8M | $978.0M | N/A | $835.6M |
| Q1 FY2025 | $22.1M+198.9% | $-65.6M | N/A | $-74.4M | $-79.2M | $918.3M | N/A | $786.2M |
| Q2 FY2025 | $11.5M-48.1% | $-76.6M | N/A | $-84.6M | $-59.9M | $1.13B | N/A | $971.5M |
| Q3 FY2025 | $2.8M-75.9% | $-82.2M | N/A | $-92.5M | $-27.1M | $1.10B | N/A | $946.3M |
| Q4 FY2025 | $2.9M+3.8% | $-87.0M | N/A | $-97.9M | $-66.7M | $1.74B | N/A | $1.58B |
| Q1 FY2026 | $34.4M+1097.4% | $-69.2M | N/A | $-84.2M | $-88.8M | $1.67B | N/A | $1.54B |
Balance Sheet Summary (Latest Period)
Kymera Therapeutics, Inc. Common Stock (KYMR) Financial Statements & Revenue History
Kymera Therapeutics, Inc. Common Stock (KYMR) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry trading at $115.47 with a market capitalization of $10. This page provides 21 historical financial statements for Kymera Therapeutics, Inc. Common Stock, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Kymera Therapeutics, Inc. Common Stock reported revenue of $39 million, a 16.7% decline from the prior year. The net profit margin of -794.0% indicates the company is currently unprofitable..
KYMR Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Kymera Therapeutics, Inc. Common Stock's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether KYMR is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track KYMR's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Kymera Therapeutics, Inc. Common Stock converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of KYMR's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use KYMR Financial Data
Investors use Kymera Therapeutics, Inc. Common Stock's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare KYMR's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how KYMR's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View KYMR's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Kymera Therapeutics, Inc. Common Stock's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.KYMR trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.